9-132927229-A-G
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000368.5(TSC1):c.182T>C(p.Leu61Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L61R) has been classified as Pathogenic.
Frequency
Consequence
NM_000368.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TSC1 | NM_000368.5 | c.182T>C | p.Leu61Pro | missense_variant | 4/23 | ENST00000298552.9 | NP_000359.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TSC1 | ENST00000298552.9 | c.182T>C | p.Leu61Pro | missense_variant | 4/23 | 1 | NM_000368.5 | ENSP00000298552 | P4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 31, 2022 | Published functional studies suggest this variant disrupts TSC1-TSC2 complex function and results in decreased levels of TSC1 and increased mTOR activity (Hoogeveen-Westerveld et al., 2011; Mozaffari et al., 2009); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23857276, 19747374, 21309039, 22867869) - |
Tuberous sclerosis 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 15, 2021 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Leu61 amino acid residue in TSC1. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this variant affects TSC1 protein function ‚Äã(PMID: 19747374) This variant has been observed in individual(s) with tuberous sclerosis complex (PMID: 19747374). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 48842). This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 61 of the TSC1 protein (p.Leu61Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. - |
Tuberous sclerosis syndrome Other:1
not provided, no classification provided | curation | Tuberous sclerosis database (TSC1) | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at